For Imperial’s Sustainability Week, medical student Urvi highlights the environmental impact of abandoned face masks.
This pandemic has unexpectedly impacted the entire world in more ways than one. Despite a whole year having passed in what feels like the blink of an eye, so many historic moments have occurred over the past year, ranging from huge political changes to unrest and activism. It’s given us a lot to reflect on and I know that I personally have realised how there is so much we can do to strive to make this world a better place.
Other than grocery shopping, leaving my house for a walk is unfortunately the only kind of outing I’ve had these days. It dawned upon me how wrongly accustomed I had become to seeing masks and gloves littered and trodden into the pavement and grass near where I lived. I don’t remember there being so much litter in my neighbourhood before. I couldn’t help but think that if this is the case in our cities and towns, imagine how many masks and gloves would be littering our beaches and rivers, let alone our oceans…
Recent graduate Samuel Badru is part of the lab team analysing samples for Imperial’s in-house Covid-19 testing scheme – here he shares the steps to processing a successful test.
I would have never guessed that five months into studying a Master’s in Molecular Biology and Pathology of Viruses, the world would be stopped in its track on account of a virus. Lockdown descended on the nation two weeks into my project, which for me meant more bioinformatics from home and no more laboratory work. Little did I know that I would return to St Mary’s Campus’ laboratories to assist in the effort to combat the COVID-19 pandemic!
I joined the College’s in-house SARS-Cov-2 testing team in October 2020 – the day after my results day (which went well!). There are a number of steps to the testing workflow that definitely seemed overwhelming at first, but after more than two months in it is all pretty much second nature. (more…)
This festive period Three Wise Women from the Faculty of Medicine will be giving us the gift of wisdom.
As vaccines bring hope, Professor Helen Ward reflects on the emotions felt and lessons learned in a year confronting COVID-19.
What a strange year. For me, it has been full of contradictions. From one moment to the next I can feel sadness, frustration, anger but also pride and satisfaction. And guilt.
Sadness at the loss of life and the chronic ill-health that COVID-19 has brought, and for the loss of livelihoods and bleak futures for even more people. Frustration at the response of political leaders when vital decisions have been delayed, and anger that the pandemic has resulted in worsening social inequalities. Pride at my small part in the response, as an advocate for public health action when needed, a researcher co-leading one of the largest epidemiological studies (REACT), and an educator delivering a rapid online course to share the science of the COVID-19 response with over 100,000 learners. But also guilt that I have a secure and well-paid job that I can do safely from home, and that I have found research this year the most stimulating and satisfying of my career. Sometimes that enjoyment seems wrong.
My research career has focused on infectious disease epidemiology, particularly the control of HIV and sexually transmitted infections (STI), alongside teaching public and global health. I look back now and see how much of my career has been training for this pandemic challenge, and has taught me lessons that are very relevant for COVID-19. From my HIV and STI research and clinical work, I learned about the complexities of controlling these infections. Understanding these “social” diseases requires a range of scientific approaches from basic immunology through mathematical modelling to anthropology. (more…)
Every time I exercise, take public transport, do my weekly food shop, socialise with those close to me, I’ve been trying to quash this invisible shield that part of my brain believes might be there, shrugging off any potential encounters with the SARS-CoV-2 virus.
I didn’t enter this trial so that I’d get a free pass to behave irresponsibly in the midst of a pandemic, which is frighteningly rearing its ugly head again in my home country. I always knew that immunity was never a certainty, having never been tested in human beings before. I was more confident that it wasn’t a dangerous thing for me to do, and certain that it was a good thing to do.
And by participating, I have certainly helped to prove both of these latter points. I’ve had two shots of the vaccine, which works by instructing my cells to make fragments of the coronavirus, thereby prompting my immune system to react and, hopefully, keep a protective memory of the threat. I’ve had no side effects at all; not even a sore arm. The devil on my shoulder sort of wished for even a little redness where the needle went in, that I could wear proudly as a mark of my contribution to research. (more…)
As the global COVID-19 pandemic draws on, effects are being felt by everyone, not just those who have been infected with the virus. From schools to offices, restaurants to gyms, many aspects of ‘normal’ have been closed, stopped, or undergone major adaptations. These societal and healthcare disruptions will affect people differently, with certain groups of people, such as those with respiratory conditions, potentially more vulnerable.
Over the last few months I have been working with Dr Nicholas Hopkinson (Respiratory Consultant, NHLI Academic, and Medical Director of the British Lung Foundation(BLF)), Dr Bradley Lonergan (Internal Medicine Trainee) in collaboration with the Asthma UK-BLF partnership, to try to understand how people with long term respiratory conditions have been impacted by measures to reduce the risk of COVID-19.
Our research published today in BMJ Open explores the findings of a large UK wide survey conducted at the height of the first wave. We found that measures to reduce risk of COVID-19, such as social distancing and changes to healthcare provision, were having profound impacts on people with long term respiratory conditions. These included cancellations of appointments, investigations, and vital aspects of their care such as pulmonary rehabilitation. (more…)
Our BSc in Remote Medicine for intercalating medical students focuses on exploring medicine in remote and low-resource environments.
Normally students would have an opportunity to travel to the Nepali Himalayas to carry out a research project. With the expedition cancelled due to Covid-19, four remote medicine students discuss how they adapted their research projects.
For my original research project, I chose to investigate sleep during an expedition to high altitude. Previous research has shown that human error is the leading cause of mountaineering accidents and at sea-level, sleep deprivation increases the risk of accidents due to human error. Therefore, my aim was to determine the contribution of the mountaineering environment to poor sleep and impaired cognitive performance on an expedition to altitude – using a reaction time application as a surrogate marker for cognitive function. Unfortunately, due to COVID-19 the planned expedition to Nepal was cancelled and so I devised a pilot study to test the reaction time application I wanted to use at altitude remotely with a small group of participants simulating a night slept at altitude in their own homes. (more…)
Three medical students reflect on how they navigated and completed their intercalated BSc research projects remotely amid the pandemic.
Ioannis Panselinas, BSc Translational Respiratory Medicine
Had someone told me back at the start of 2020 what the year would have in store, I would have probably said that they had stolen ideas from an Orwellian dystopia. Yet the world is currently in the grips of one of the most terrible pandemics in living memory. And among all the global disruption were us 4th year Imperial medics having to face a transition to remote working in the middle of project period. Unsurprisingly, lab work cannot be done from the comfort of our homes. So, as COVID-19 hit the UK, we were forced to cut short our experiments and were ultimately left with a looming deadline and a project to complete. In retrospect, I think I can sum up my experience with the 5 stages of COVID disruption:
Justine is taking part in Imperial’s COVID-19 vaccine clinical trial – here she shares her experience of receiving the first dose.
It’s a strange feeling that as I write this, the cells in my arm are reading a message that scientists planted there just hours ago.
That message – a strip of genetic code – contains the recipe for making part of the virus that causes COVID-19, SARS-CoV-2. This is the ‘spike’ protein that the virus uses to lock on to cells and invade them. The hope is that by telling my cells to churn out this molecule, my immune system will launch an effective and lasting response that could make me immune to the coronavirus.
That’s the theory, anyway; we won’t know whether this experimental vaccine works until scientists have carried out rigorous clinical studies and gathered enough data to be confident of how safe and effective it is. And today I was part of that clinical research.
I’m one of 120 people who have so far been selected to take part in one of the earliest phases of a clinical trial that’s testing Imperial’s newly-developed coronavirus vaccine. As soon as I spotted that the trial was recruiting participants, I immediately slotted my details into the online form to express my interest in joining, and eagerly awaited a response. (more…)
Four Imperial researchers recount their experiences of volunteering at one of the mega-labs built to scale up COVID-19 testing in the UK.
Since March, the UK Biocentre laboratories located in Milton Keynes has become one of four Lighthouse Labs (the others are in Glasgow, Alderley Park in Cheshire and Cambridge) – the largest network of diagnostic testing facilities in British history. Every day the team process and analyse around 30,000 swab samples from across the country to test for the presence of the SARS-CoV-2 virus that causes COVID-19. They use a combination of manual processing and high-throughput robots to inactivate the viral samples, extract the RNA and analyse them with a technique known as quantitative polymerase chain reaction (qPCR) to detect the presence of the virus.
The UK Biocentre labs were uniquely placed to help in the testing efforts, as in normal life they are usually home to around 30 staff processing and archiving clinical samples from hospitals around the UK. 200 volunteers across academia, civil service and industry answered a call to support with COVID-19 testing, including several PhD students and postdocs from Imperial. As their secondments draw to a close, we speak to some of the volunteers to hear about their experience: (more…)
Jenny Shelton highlights the potential for invasive and chronic fungal lung infections with Aspergillus fumigatus in COVID-19 patients and the dangers posed by growing antifungal resistance.
Virtually unknown just a few months ago, the COVID-19 pandemic has affected millions worldwide. The pathogen responsible, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infects alveolar cells in the lungs. Parallels are already emerging between severe COVID-19 infection and severe influenza. Influenza, or ‘the flu’, is also caused by a virus that infects cells along the respiratory tract and is associated with similar symptoms to COVID-19 but has a lower death rate (<0.1%). Studies have found that up to 65% of individuals hospitalised with severe influenza infection are co-infected with bacteria. A recent review found 9 studies, undertaken in China and USA, that reported bacterial coinfection in a combined 62 of 806 (8%) individuals admitted to hospital with COVID-19 infection and the majority of patients (72%) received antimicrobial drugs.
Another secondary infection associated with severe influenza is invasive pulmonary aspergillosis (IPA), which develops when spores from the fungus Aspergillus fumigatus grow in the lung and pass into the bloodstream to cause sepsis. IPA is diagnosed in up to 19% of individuals hospitalised with influenza, with significantly higher mortality in the patients with IPA. (more…)